Barbara Handelin joined DNAPrint Pharmaceuticals, the newly organized subsidiary of DNAPrint Genomics, as director of diagnostics, the company said this week.
Since 1987, Handelin was director of the DNA Diagnostics Laboratory at Integrated Genetics (now Genzyme Genetics).
She earned her PhD at the Oregon Health Sciences University and the Massachusetts Institute of Technology.
The National Human Genome Research Institute named the husband-and-wife scientific team, Joan Bailey-Wilson and Alexander Wilson, as co-chiefs of its Inherited Disease Research Branch, the agency said this week.
Currently, Bailey-Wilson heads Statistical Genetics and Wilson heads Genometrics at Inherited Disease Research, one of the seven research branches in NHGRI's Division of Intramural Research.
Wilson and Bailey-Wilson received their BA degrees from McDaniel College and PhD degrees in medical genetics from Indiana University Medical Center in Indianapolis.
Robin Toft has joined the board of directors at Innovative Biosensors, the company announced earlier this week.
Toft was formerly the senior vice-president of commercial operations at Roche Molecular Systems and vice-president of sales and marketing at ViroLogic (now known as Monogram Biosciences) prior to that. At Laboratory Corporation of America, she was the head of marketing, sales, and business development for company's Center for Molecular Biology and Pathology.
Thomas Caskey is the new director and CEO-elect of the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, the University of Texas system said late last week.
Caskey has been an adjunct professor and an original member of the institute's Scientific Advisory Board since 2004.
Caskey was founding director of Houston-based Cogene Biotech Ventures and Cogene Ventures, venture capital funds supporting early-stage biotechnology and life sciences companies. He was senior vice president for human genetics and vaccines discovery at Merck Research Laboratories from 1994 to 2000 and president of the Merck Genome Research Institute from 1998 to 2000.
Caskey earned his medical degree from Duke University School of Medicine and his undergraduate degree from the University of South Carolina. He serves as an adjunct professor in the Department of Molecular & Human Genetics at Baylor College of Medicine.
Part of the university system's Health Science Center at Houston, the institute will also retain Nobel Laureate Ferid Murad as director and Irma Gigli as deputy director.
Amicus Therapeutics appointed David Lockhart as chief scientific officer, the company announced late last week.
Lockhart most recently was president and chief scientific officer of Ambit Biosciences in San Diego, Calif. He was the director of genomics at the Genomics Institute of the Novartis Research Foundation.
As vice-president of genomics research, he was the primary developer of DNA arrays for genome-wide gene expression profiling at Affymetrix.
Lockhart received his PhD in chemistry from Stanford University and was a postdoctoral fellow at the Whitehead Institute at MIT under Peter Kim.
Xenomics named David Robbins as vice-president of product development to accelerate the commercialization of non-invasive technology based on Transrenal-DNA, the company said last week.
Robbins led the development and FDA approval of Abbott Diagnostic's Hepatitis A line of diagnostic products. He oversaw SmithKline's molecular diagnostic laboratory.
He holds a doctorate in chemistry from the University of Texas at Austin.
CombiMatrix last week announced a new line of Species-Specific MicroRNA arrays on its CustomArray platform.
The company is offering arrays for human, mouse, rat, C. elegans, Drosophila, Arabidopsis, and maize, priced at $99 per array. A compendium array, featuring all known microRNAs, is also being sold, CombiMatrix said.
Agilent Technologies this week launched its dual-mode, one-color/two-color microarray platform, which it claims can be used for either one-color or two-color experiments to match researchers' requirements.
The dual-mode microarrays use Agilent's 60-mer probes printed through its inkjet in situ microarray manufacturing process. In addition, Agilent said data created using the dual-mode arrays has recently been submitted to the US Food and Drug Administration's Microarray Quality Control project.